Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.77 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.77 |
| ▸ | STAT3 | P40763 | 1/20 | 0.61 |
| ▸ | CCNK | O75909 | 1/20 | 0.57 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | CDK9 | P50750 | 1/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305312 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL19692453 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL29842899 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL21294522 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL22959658 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL23832857 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL19692342 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL30305317 | 1.00 | CRBN (0.77) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL19692300 | 0.99 | CRBN (0.78) | CRBNDDB1STAT3CCNKCDK12 | |
| SCHEMBL30275753 | 0.99 | CRBN (0.78) | CRBNDDB1STAT3CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552775-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240131169-A1 | CLIPTAC COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-03-28 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-11786600-B2 | Cliptac composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11786600-B2 | Cliptac composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11786600-B2 | Cliptac composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4019021-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021257650-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021257650-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021057872-A1 | PROTAC SMALL MOLECULE COMPOUND AND APPLICATION THEREOF | 珠海宇繁生物科技有限责任公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-3787747-A1 | SMALL MOLECULE DEGRADERS OF POLYBROMO-1 (PBRM1) | Dana-Farber Cancer Institute, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190275161-A1 | CLIPTAC COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| US-20190275161-A1 | CLIPTAC COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| WO-2017212329-A1 | CLIPTAC COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017212329-A1 | CLIPTAC COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101534-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885STAT3 3997/4885 |
| US-12552775-B2 | Compounds and uses thereof | SMARCC1, SMARCC2, CHD1 | CRBN 125/4885DDB1 484/4885STAT3 1313/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885STAT3 3997/4885 |
| US-11786600-B2 | Cliptac composition | UBE3C, CBLC, STUB1 | CRBN 92/4885DDB1 396/4885STAT3 2616/4885 |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | SNCA, ADRM1, UBE3C | CRBN 139/4885DDB1 557/4885STAT3 3633/4885 |
| US-20190275161-A1 | CLIPTAC COMPOSITION | UBE3C, CBLC, STUB1 | CRBN 92/4885DDB1 396/4885STAT3 2616/4885 |
| US-20240131169-A1 | CLIPTAC COMPOSITION | UBE3C, CBLC, STUB1 | CRBN 92/4885DDB1 396/4885STAT3 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.